The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
The director of the Dartmouth Epilepsy Program and chairwoman of AES 2020 discussed some of the major topics from the previously completed annual meeting and where epilepsy research is trending.
The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.
The director of the Dartmouth Epilepsy Program discussed a few of the notable highlights and themes from the recently completed American Epilepsy Society Annual Meeting.
Specific health-related quality of life measures in physical activities, well-being, cognition, and social activities were improved among those who underwent the laser ablation procedure.
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.
The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.
The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to try and find the right medications for their patients as early as possible.
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team succeeded at titrating cenobamate early in the study.
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team studied the interactions of ASMs and cenobamate.
The director of the Mid-Atlantic Epilepsy and Sleep Center also noted how serious adverse effects from treatment can be detrimental to patients’ lives.
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team worked to reduce deleterious ASM interactions.
The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed how the treatment landscape for patients with Lennox-Gastaut syndrome could alter if fenfluramine is approved.
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients with intractable epilepsy found cenobamate effective.
The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health provided his insight on the reasons for the limited number of FDA-approved seizure forecasting devices.
Eric Segal, MD, director of pediatric epilepsy, HMH Hackensack University Medical Center, detailed his study on diazepam nasal spray in patients with and without antiseizure medications.
